178 related articles for article (PubMed ID: 23002158)
1. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
[TBL] [Abstract][Full Text] [Related]
2. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks DJ; Torjanski N; Burn DJ
J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
[TBL] [Abstract][Full Text] [Related]
4. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
Ahlskog JE
Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
[TBL] [Abstract][Full Text] [Related]
5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
6. Medical hazards of the internet: gambling in Parkinson's disease.
Larner AJ
Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
[No Abstract] [Full Text] [Related]
7. [Advances in the medical treatment of Parkinson's disease].
Chaná P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S22-5. PubMed ID: 20082996
[TBL] [Abstract][Full Text] [Related]
8. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
9. [Hallucinations in Parkinson's disease].
Moser A; Hagenah J; Kömpf D
Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
[No Abstract] [Full Text] [Related]
11. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
Klos KJ; Bower JH; Josephs KA; Matsumoto JY; Ahlskog JE
Parkinsonism Relat Disord; 2005 Sep; 11(6):381-6. PubMed ID: 16109498
[TBL] [Abstract][Full Text] [Related]
12. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
13. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
16. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
[TBL] [Abstract][Full Text] [Related]
17. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
18. Sleep attacks in Parkinson's disease.
Pirker W; Happe S
Lancet; 2000 Aug; 356(9229):597-8. PubMed ID: 10950264
[No Abstract] [Full Text] [Related]
19. Pramipexole, ropinirole, and mania in Parkinson's disease.
Singh A; Althoff R; Martineau RJ; Jacobson J
Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
[No Abstract] [Full Text] [Related]
20. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
Defer GL
Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
[No Abstract] [Full Text] [Related]
[Next] [New Search]